ENTO Insider Trading Activity and SEC Form 4 Filings
ENTO insider trading summary
No open-market insider purchases or sales of Entero Therapeutics, Inc. (ENTO) have been reported on SEC Form 4 in the past 12 months.
Latest ENTO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 6, 2025 | Sarah Romano | Chief Financial Officer | Sell | $465 (727 @ $0.64) |
| Oct 9, 2024 | Sarah Romano | Chief Financial Officer | Sell | $212 (476 @ $0.45) |
| Jul 2, 2024 | James Sapirstein | Chairman and CEO | Sell | $1K (1,289 @ $1.07) |
| Jul 2, 2024 | Sarah Romano | Chief Financial Officer | Sell | $664 (621 @ $1.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.